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2-Year Clinical and Angiographic Outcomes
From a Randomized Trial of Polymer-Free
Dual Drug-Eluting Stents Versus Polymer-Based
Cypher and Endeavor, Drug-Eluting Stents
Robert A. Byrne, MB,* Adnan Kastrati, MD,* Klaus Tiroch, MD,* Stefanie Schulz, MD,*
Jürgen Pache, MD,* Susanne Pinieck,* Steffen Massberg, MD,* Melchior Seyfarth, MD,*
Karl-Ludwig Laugwitz, MD,† Katrin A. Birkmeier, MD,* Albert Schömig, MD,† Julinda Mehilli, MD,*
for the ISAR-TEST-2 Investigators
Munich, Germany
Objectives In the ISAR-TEST-2 (Intracoronary Stenting and Angiographic Results: Test Efficacy of Three Limus-Eluting Stents)
randomized trial, a new-generation sirolimus- and probucol-eluting stent (Dual-DES) demonstrated a 12-month
efficacy that was comparable to sirolimus-eluting stents (SES) (Cypher, Cordis Corp., Warren, New Jersey) and
superior to zotarolimus-eluting stents (ZES) (Endeavor, Medtronic CardioVascular, Santa Rosa, California). The
aim of the current study was to investigate the comparative clinical and angiographic effectiveness of SES, Dual-
DES, and ZES between 1 and 2 years.
Background Long-term polymer residue is implicated in adverse events associated with delayed vessel healing after drug-
eluting stent therapy. The second-generation ZES utilizes an enhanced biocompatibility polymer system whereas
a new-generation Dual-DES employs a polymer-free drug-release system.
Methods A total of 1,007 patients undergoing coronary stenting of de novo lesions in native vessels were randomized to
treatment with SES (n  335), Dual-DES (n  333), or ZES (n  339). Clinical follow-up was performed to 2
years. Angiographic follow-up was scheduled at 6 to 8 months and 2 years.
Results There were no significant differences between groups regarding death/myocardial infarction (SES: 10.2% vs.
Dual-DES: 7.8% vs. ZES: 9.2%; p  0.61) or definite stent thrombosis (SES: 0.9% vs. Dual-DES: 0.9% vs. ZES:
0.6%; p  0.87). Two-year target lesion revascularization (TLR) was 10.7%, 7.7%, and 14.3% lesions in the SES,
Dual-DES, and ZES groups, respectively (p  0.009). Incident TLR between 1 and 2 years in the Dual-DES group
(0.9%) was significantly lower than in the Cypher SES group (3.6%) (p  0.009), but comparable to the Endeavor
ZES group (0.7%) (p  0.72). These findings mirrored those observed for binary restenosis.
Conclusions At 2 years, there was no signal of a differential safety profile between the 3 stent platforms. Furthermore, the
antirestenotic efficacy of both Dual-DES and ZES remained durable between 1 and 2 years, with Dual-DES main-
taining an advantage over the entire 2-year period. (Intracoronary Stenting and Angiographic Results: Test Effi-
cacy of Three Limus-Eluting Stents [ISAR-TEST-2]; NCT00332397) (J Am Coll Cardiol 2010;55:2536–43)
© 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.020f
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June 8, 2010:2536–43 2-Year Follow-Up of SES Versus Dual-DES Versus ZESare-metal stents. These events are comprised of a small, but
ignificant, excess of stent thrombosis, but also perhaps, a
arginal erosion of antirestenotic efficacy (2–5). Although
ultifactorial in origin, pathological and pre-clinical research
ata strongly implicate polymer residue as a key etiological
actor (1,6).
The ISAR-TEST-2 (Intracoronary Stenting and Angio-
raphic Results: Test Efficacy of Three Limus-Eluting Stents)
tudy is a 2-center, investigator-initiated randomized trial (7).
e enrolled 1,007 patients across the spectrum of coronary
isease presentations and allocated participants to treatment
ith the first-generation permanent polymer sirolimus-eluting
tent (SES) (Cypher, Cordis Corp., Warren, New Jersey), a
olymer-free sirolimus- and probucol-eluting stent (Dual-
ES), or a biocompatible polymer zotarolimus-eluting stent
ZES) (Endeavor, CardioVascular, Santa Rosa, California) in
trial powered for an angiographic end point. At 6 to 8
onths, there was a significant difference in the primary end
oint across the treatment groups: binary restenosis in the
ual-DES group (11.0%) was significantly lower than that
n the ZES group (19.3%; p  0.002), but comparable to
hat in the SES group (12.0%; p  0.68) (7).
As potential differences between first-, second-, and
ext-generation DES may be expected to appear with
onger-term follow-up, we investigated safety and efficacy
utcomes of patients enrolled in the ISAR-TEST-2 trial by
nalyzing clinical and angiographic data out to 2 years.
ethods
tudy population and protocol. The methods of the
SAR-TEST-2 trial have been previously reported (7). In
rief, eligible patients were older than age 18 years with
schemic symptoms or evidence of myocardial ischemia in
he presence of 50% de novo stenosis located in native
oronary vessels. Key exclusion criteria included patients
ith target lesion located in the left main stem, in-stent
estenosis, cardiogenic shock, malignancies or other comor-
id conditions with life expectancy 12 months, known
llergy to the study medications (aspirin, clopidogrel, siroli-
us, stainless steel), or pregnancy or positive pregnancy test.
Full details of treatment allocation, study devices, and
djunctive antithrombotic therapy are previously reported (7).
n oral loading dose of 600 mg clopidogrel was administered
o all patients prior to the intervention. After the intervention,
ll patients received 200 mg/day aspirin indefinitely, clopi-
ogrel 150 mg for the first 3 days (or until discharge) followed
y 75 mg/day for 12 months, and other cardiac medications
ccording to the judgment of the patient’s physician (e.g.,
eta-blockers, ACE inhibitors, statins, and so on).
ata management and follow-up. Patients were followed-up
ither by physician office visit or by telephone at 6 to 8 months,
year, and 2 years. Relevant clinical data were collected and
ntered into a computer database by specialized personnel
f the ISAResearch Centre, Deutsches Herzzentrum. Clin-
cal events were adjudicated by an independent Clinical uvent Adjudication Committee.
nd point adjudication was fully
linded to randomly assigned stent
ype. Angiographic follow-up was
cheduled at 2 time points follow-
ng coronary intervention, namely
to 8 months and 2 years. Base-
ine, post-procedural, and follow-up
oronary angiograms were digitally
ecorded and assessed offline in the
ndependent quantitative angio-
raphic core laboratory (ISAR-
search Centre, Deutsches Herz-
entrum) with an automated edge-detection system (CMS
ersion 7.1, Medis Medical Imaging Systems, Leiden, the
etherlands) by 2 experienced operators unaware of the
reatment allocation. All measurements were performed on
ineangiograms recorded after the intracoronary administra-
ion of nitroglycerin using the same single worst-view projec-
ion at all times. The contrast-filled nontapered catheter tip
as used for calibration. Quantitative analysis was performed
n both the “in-stent” and “in-segment” areas (including the
tented segment, as well as both 5-mm margins proximal and
istal to the stent).
nd points and definitions. The principal safety end
oints of interest in the current analysis were the composite
f death and myocardial infarction and the rate of definite
tent thrombosis at 2 years. The principal efficacy end point
as target lesion revascularization (TLR) at 2 years. Delta-
LR was the difference in TLR events between 1 and 2
ears. The adjudication of TLR required the documentation
f symptoms or objective signs of ischemia prior to perfor-
ance of coronary angiography. The angiographic end
oint of interest was overall binary in-segment restenosis. In
nalyzing 2-year angiographic outcomes, we used a com-
osite analysis based on the latest angiographic follow-up
vailable for an individual patient (whether at 6 to 8 months
r 2 years) (4). The diagnosis of myocardial infarction
equired the presence of new Q waves on the electrocardio-
ram and/or elevation of creatine kinase or its MB isoform
o at least 3 times the upper limit of normal in no fewer than
blood samples. Stent thrombosis was classified according
o Academic Research Consortium criteria.
tatistical analysis. The results of the primary analysis
ave already been published, and this additional analysis is
xploratory in nature. Baseline descriptive statistics are
resented as frequencies and percentages for categorical
ariables and mean  SD or median (interquartile range)
or continuous variables. Survival and event-free status were
ssessed using the methods of Kaplan-Meier. Differences
cross groups were checked for significance (depending on
he distribution of the data) with analysis of variance or
ruskal-Wallis test (continuous data), contingency table
nalysis (categorical variables), or log-rank test (survival
nalysis). Intergroup outcome comparisons were assessed
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
Dual-DES  sirolimus- and
probucol-eluting stent(s)
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
ZES  zotarolimus-eluting
stent(s)sing the Student t test (continuous data), chi-square or
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2-Year Follow-Up of SES Versus Dual-DES Versus ZES June 8, 2010:2536–43isher exact test (categorical variables), or log-rank test
survival analysis). Statistical software S-PLUS, version 4.5
Insightful Corp., Seattle, Washington) was used for all
nalyses.
esults
s previously reported, a total of 1,007 patients were enrolled
n this study: 335 patients received SES, 333 were treated with
ual-DES, and 339 received ZES. Baseline clinical, angio-
raphic, and procedural characteristics were similar across all 3
reatment groups (Table 1).
-year clinical outcomes. Clinical follow-up data at 2
ears were available for all but 65 of the 1,007 enrolled
atients (Table 2). Among these 65 patients, median
Baseline CharacteristicsTable 1 Baseline Characteristics
Patients
Female 7
Age, yrs 66
Diabetes 9
Hypertension 21
Current smoker 5
Hyperlipidemia 23
Coronary disease
1-vessel 4
2-vessel 8
3-vessel 20
Multivessel disease 28
Clinical presentation
Myocardial infarction 4
Unstable angina 8
Stable angina 20
Prior myocardial infarction 10
Prior aortocoronary bypass surgery 2
Left ventricular ejection fraction 52
Number of lesions treated per patient 1.2
Lesions
Target vessel
Left anterior descending artery 20
Left circumflex artery 10
Right coronary artery 10
Ostial 5
Bifurcational 8
Total occlusion 4
Chronic 1
Complex (type B2/C) lesions 30
Lesion length, mm 14
Vessel size, mm 2.7
Balloon-to-vessel ratio 1.1
Minimal luminal diameter post-procedure, mm
In-stent 2.5
In-segment 2.2
Diameter stenosis post-procedure, %
In-stent 10
In-segment 23Values are n, n (%), or mean  SD.
Dual-DES  sirolimus- and probucol-eluting stent(s); SES  sirolimus-elutinollow-up was 21 months (interquartile range 20 to 22
onths).
Regarding safety outcomes, the composite of death or MI
t 2 years had occurred in 34 cases (10.2%) with SES, 26
ases (7.8%) in Dual-DES, and 31 cases (9.2%) with ZES
p  0.61) (Fig. 1). Definite stent thrombosis occurred in 3
atients (0.9%) each with SES and Dual-DES and 2 cases
0.6%) with ZES (p 0.88). There were no additional cases
f definite stent thrombosis after 12 months.
At 2 years, TLR had been performed in 45 of 419
10.7%), 33 of 427 (7.7%), and 60 of 420 (14.3%) lesions in
he SES, Dual-DES, and ZES groups, respectively (p 
.009). In terms of pairwise comparisons, only the difference
etween Dual-DES and ZES was significant (p  0.006).
Dual-DES ZES p Value
333 339
.7) 76 (22.8) 83 (24.5) 0.83
1.1 67.0 11.2 67.2 10.9 0.65
.2) 96 (28.8) 89 (26.3) 0.75
.9) 229 (64.9) 229 (67.6) 0.58
.3) 66 (19.8) 61 (18.0) 0.69
.0) 209 (62.8) 222 (65.5) 0.24
0.30
.3) 64 (19.2) 59 (17.4)
.4) 86 (25.8) 74 (21.8)
.3) 183 (55.0) 206 (60.8)
.7) 269 (80.8) 280 (82.6) 0.23
0.50
.4) 40 (12.0) 49 (14.5)
.4) 101 (30.3) 101 (29.8)
.2) 192 (57.7) 189 (55.8)
.9) 84 (25.2) 88 (26.0) 0.35
) 33 (9.9) 29 (8.6) 0.68
2.0 53.0 12.0 54.5 10.4 0.19
.53 1.28 0.51 1.24 0.45 0.42
427 420
0.10
.7) 187 (43.8) 172 (41.0)
.3) 107 (25.1) 128 (30.5)
.0) 133 (31.1) 120 (28.6)
.4) 48 (11.2) 55 (13.1) 0.60
.5) 78 (18.3) 94 (22.4) 0.33
.5) 50 (11.7) 52 (12.4) 0.91
) 24 (5.6) 16 (3.8) 0.39
.0) 297 (69.6) 315 (75.0) 0.20
.3 14.0 8.2 14.7 8.0 0.17
.46 2.69 0.52 2.71 0.49 0.10
.07 1.11 0.07 1.11 0.08 0.11
.43 2.49 0.48 2.51 0.47 0.07
.51 2.18 0.58 2.14 0.54 0.20
.7 11.6 5.0 10.7 7.0 0.014
1.0 23.2 11.8 24.2 11.7 0.18SES
335
6 (22
.6 1
1 (27
4 (63
8 (17
1 (69
8 (14
5 (25
2 (60
7 (85
5 (13
5 (25
5 (61
0 (29
7 (8.1
.4 1
5 0
419
4 (48
6 (25
9 (26
6 (13
6 (20
8 (11
7 (4.1
6 (73
.8 8
5 0
0 0
5 0
0 0
.8 5
.5 1g stent(s); ZES  zotarolimus-eluting stent(s).
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roup (4 lesions [TLR: 0.9%]) was significantly lower than
ith the Cypher SES (15 lesions [TLR: 3.6%]) (p 
.009) but comparable to that observed with the Endeavor
ES (3 lesions [TLR: 0.7%]) (p  0.72) (Fig. 2).
erial angiographic follow-up at 2 years. Of the 828
atients with first angiographic follow-up, 80 patients
nderwent a re-intervention procedure during the same
ngiographic session, and 15 died prior to the scheduled
econd angiographic follow-up. Of the remaining 733
ligible patients, 493 patients (67.3%) had re-angiography
Clinical Events at 1 and 2 YearsTable 2 Clinical Events at 1 and 2 Years
Patients
1 yr
Definite stent thrombosis
Probable stent thrombosis
Possible stent thrombosis
Death
Myocardial infarction
Death/myocardial infarction
Death/myocardial infarction/target lesion revascularizati
2 yrs
Definite stent thrombosis
Probable stent thrombosis
Possible stent thrombosis
Death
Myocardial infarction
Death/myocardial infarction
Death/myocardial infarction/target lesion revascularizati
Data are shown as n (%); percentages are Kaplan-Meier estimates.
Abbreviations as in Table 1.
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Figure 1 Kaplan-Meier Estimates of Death/Myocardial Infarctio
Dual-DES  sirolimus- and probucol-eluting stent(s); SES  sirolimus-eluting stentt 2 years. Relevant angiographic follow-up data are shown
n Table 3.
Two-year composite binary restenosis (based on latest
ngiographic follow-up available for an individual pa-
ient) occurred in 65 of 350 (18.6%) lesions with SES, 48
f 345 (13.9%) lesions with Dual-DES, and 75 of 358
20.9%) lesions with ZES (p  0.047). In terms of
airwise comparisons, only the difference between Dual-
ES and ZES was significant (p  0.014). Incident
inary restenosis between 1 and 2 years in the Dual-DES
roup (10 lesions [delta-restenosis: 2.9%]) was signifi-
SES Dual-DES ZES p Value
335 333 339
3 (0.9) 3 (0.9) 2 (0.6) 0.87
0 0 1 (0.3) 0.37
2 (0.6) 3 (0.9) 1 (0.3) 0.59
9 (2.7) 8 (2.4) 12 (3.5) 0.66
12 (3.6) 14 (4.2) 11 (3.2) 0.80
20 (6.0) 20 (6.0) 21 (6.2) 0.99
46 (13.7) 44 (13.2) 66 (19.5) 0.045
3 (0.9) 3 (0.9) 2 (0.6) 0.87
1 (0.3) 0 2 (0.6) 0.37
4 (1.2) 4 (1.2) 2 (0.6) 0.67
18 (5.4) 14 (4.2) 21 (6.2) 0.52
18 (5.4) 15 (4.5) 13 (3.9) 0.65
34 (10.2) 26 (7.8) 31 (9.2) 0.61
68 (20.4) 52 (15.6) 77 (22.7) 0.06
12 14 16 18 20 22 24
ndomization
Dual-DES
ZES
SES
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t to 2 Years
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2-Year Follow-Up of SES Versus Dual-DES Versus ZES June 8, 2010:2536–43antly lower than with the Cypher SES (23 lesions
delta-restenosis: 6.6%]) (p  0.023) but comparable to
hat observed with the Endeavor ZES (6 lesions [delta-
estenosis: 1.6%]) (p  0.28) (Fig. 3).
We checked whether there were significant differences
cross the 3 study groups among the eligible patients who
id not undergo 2-year re-angiography (n  240). We
bserved no significant differences in any of the baseline,
esion, or procedural characteristics listed in Table 1 with
he exception of luminal caliber pre-intervention (minimal
uminal diameter with SES: 0.90  0.50 mm, Dual-DES:
.99  0.51 mm, ZES: 1.10  0.47 mm; p  0.028;
tenosis: 67.8  16.2%, 65.3  16.1%, 61.3  13.5%; p 
.018).
7.2
10.7
0
5
10
15
20
25
1 yr 2 yrs
Ta
rg
et
 le
sio
n
re
va
sc
u
la
riz
at
io
n,
 %
Δ = 3.5%
SES
p=0.009
1
Figure 2 Clinical Restenosis
Target lesion revascularization at 1 and 2 years. Abbreviations as in Figure 1.
Angiographic Data at 6 to 8 Months and CompoTable 3 Angiographic Data at 6 to 8 Month
S
Lesions 3
6–8 months
Minimal luminal diameter, in-stent, mm 2.32
Minimal luminal diameter, in-segment, mm 1.99
Diameter stenosis, in-stent 20.1
Diameter stenosis, in-segment 31.8
Late luminal loss, in-stent, mm 0.24
Binary restenosis, in segment 42
2-yr composite
Minimal luminal diameter, in-stent, mm 2.22
Minimal luminal diameter, in-segment, mm 1.95
Diameter stenosis, in-stent 23.6
Diameter stenosis, in-segment 33.1
Late luminal loss, in-stent, mm 0.35
Binary restenosis, in segment 65Data shown as mean  SD or n (%), unless otherwise specified.
Abbreviations as in Table 1.iscussion
he ISAR-TEST-2 trial was a 2-center randomized trial
omparing the safety and efficacy of 3 limus-eluting stents,
amely, the first-generation Cypher SES, a novel polymer-
ree dual sirolimus- and probucol-eluting stent, and the
econd-generation Endeavor ZES. The 2-year results are of
nterest for 2 reasons: 1) the occurrence of safety events
eyond 12 months was rare; there was no signal of a
ifferential safety profile across the groups out to 2 years;
nd 2) the antirestenotic efficacy of both Dual-DES and
ES remained durable between 1 and 2 years, with Dual-
ES maintaining an advantage over the entire 2-year
eriod; against this there was evidence of a slight decrement
13.6 14.3
7.7
Δ = 0.7% 0.9%
ZESal-DES
p=0.72
2 yrs 1 yr 2 yrs
Angiographic Data at 2 YearsComposite Angiographic Data at 2 Years
Dual-DES ZES p Value
345 358
2.26 0.64 1.95 0.72 0.001
1.98 0.59 1.79 0.66 0.001
20.0 17.1 30.0 21.2 0.001
30.5 16.6 35.3 19.4 0.001
0.23 0.50 0.58 0.55 0.001
38 (11.0) 69 (19.3)
2.19 0.69 1.96 0.73 0.001
1.95 0.65 1.83 0.69 0.030
22.4 19.0 29.3 21.8 0.001
31.0 17.8 34.1 20.4 0.20
0.30 0.54 0.57 0.57 0.001
48 (13.9) 75 (20.9) 0.0476.8
Δ =
Du
 yrsites and
ES
50
 0.63
 0.59
 16.8
 15.4
 0.51
(12.0)
 0.69
 0.63
 20.4
 18.2
 0.60
(18.6)
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ES.
With the passage of time, we have come to realize that
he undoubted efficacy of first-generation DES in prevent-
ng coronary restenosis has been achieved at the expense of
delay in healing of the stented arterial segment. Although
ultifactorial in origin, pathological and pre-clinical re-
earch data strongly implicate polymer residue as a key
tiological factor (1,6). This concern has focused attention
n the development of newer DES providing high antirest-
notic efficacy with lesser impact on arterial healing. The
urrent trial deals with 2 such devices and permits some
nsight into the comparatively late performance of both
latforms.
The second-generation Endeavor ZES has attempted to
ddress the issue of impaired vascular healing by utilizing a
hin-strut (91-m) cobalt chromium backbone—which
auses less acute arterial injury—and an enhanced biocom-
atibility polymer system—which is hypothesized to reduce
edium- to long-term inflammatory response. Pre-clinical
esearch studies support the validity of this design concept
ith evidence of earlier and more complete endothelializa-
ion in both porcine and rabbit iliac models (8,9). The
rawback of this device is that the polymer system employed
esults in relatively rapid drug-release kinetics (95% of drug
issociated at 14 days), which translate into a somewhat
educed early antirestenotic efficacy (10). The 2-year results
f the ISAR-TEST-2 trial support the characterization of
he Endeavor ZES as a rapid-release, early-healing DES
evice: 6- to 8-month late loss and binary restenosis were
elatively high, and there was a low incidence of TLR and
inary restenosis between 1 and 2 years. These findings are
12.0
18.6
0
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∆ = 6.6%
p=0.023 
6
Figure 3 Angiographic Restenosis
Binary angiographic restenosis at 6 to 8 months and composite binary angiographn keeping with the early and late performance of the ZES on the recently reported ENDEAVOR-IV (Randomized
omparison of Zotarolimus-Eluting and Paclitaxel-Eluting
tents in Patients with Coronary Artery Disease) clinical
rial (11,12).
The Dual-DES also incorporates a thin-strut stent back-
one (87-m stainless steel), but uses a polymer-free
rug-release system. In order to offset the somewhat lower
ntirestenotic efficacy of a quick-release polymer-free plat-
orm, the Dual-DES incorporates a second drug—
robucol—targeted at a different element of the restenotic
esponse cascade. In addition, by virtue of its lipophilicity, it
etards the release of the sirolimus (such that approximately
0% of the drug is eluted at 14 days) (13). Probucol is a
otent lipophilic antioxidant typically orally administered
nd has proven effective in inhibiting this restenotic re-
ponse to balloon injury both in animal models and clinical
rials (14,15). It has a low therapeutic index when admin-
stered systemically (15)—a feature that makes it better
uited to local tissue-specific delivery systems.
Porcine model research has demonstrated signs of im-
roved vascular healing with the Dual-DES at 30 days (13),
nd this device has demonstrated high antirestenotic efficacy
t 6 to 8 months (mean late loss: 0.23  0.50 mm),
omparable to that of the Cypher SES in the current
elatively unselected cohort of patients with intermediate-
o-high disease complexity (7). The present 2-year analysis
upports the durability of antirestenotic efficacy with this
evice with a low rate of incident TLR and binary restenosis
etween 1 and 2 years (TLR: 0.9%). This is in keeping
ith the conjectured late performance advantage of a
olymer-free drug-elution system over a durable polymer-
ased device. In addition, a polymer-free DES might
19.3
20.9
13.9
ZESl-DES
∆ = 1.6% 2.9%
p=0.28
    2 yrs 6-8 m    2 yrs
enosis at 2 years. Abbreviations as in Figure 1.11.0
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hetical at present.
In the current report, there was a slight decrement in
ntirestenotic efficacy with the Cypher SES between 1 and
years. In particular, the rate of TLR with the Cypher
tent (3.5%) was significantly higher than that with both the
ual-DES and ZES. The observation of a small magnitude
catch up” in antirestenotic efficacy with polymer-based
ES has previously been described in earlier reports
4,5,16,17).
A central feature of the ISAR-TEST-2 study was the
cheduling of serial angiographic follow-up for all patients
t 2 time points post-stent implantation, namely, 6 to 8
onths and 2 years. Surveillance angiographic follow-up
as proven useful in the evaluation of the temporal course of
ntirestenotic efficacy following plain balloon angioplasty,
are-metal stenting, and DES therapy (4,18,19). However,
uch follow-up is likely to inflate the rates of revasculariza-
ion in a manner that is not reflective of routine clinical
ractice. Although this may distort the absolute magnitude
f differences in interdevice efficacy, the relative magnitude
ay be expected to be real (20). An important caveat
elating to angiographic surveillance concerns the issue of
issing data. In particular, patients with higher initial
estenosis at 6 to 8 months tend not to be represented in
-year angiographic data as they are likely to have under-
one initial TLR. Reporting composite data analysis at-
empts to capture information on these patients (4). Fur-
hermore, serial angiographic observations should never be
onsidered in isolation but rather always in parallel with
verall 2-year TLR. Finally, it should be acknowledged that
he proportion of eligible patients who underwent 2-year
ngiography is relatively low (67.3%). This is unlikely to
ave introduced significant bias for 2 reasons. First, char-
cteristics of patients who did not undergo angiographic
ollow-up were well matched across the groups. Second, the
esults of angiographic restenosis are concordant with re-
ults relating to clinical restenosis for which data were
vailable on a very high proportion of patients.
Some additional limitations of our report should be
cknowledged. The ISAR-TEST-2 trial was a comparative
fficacy trial with a 6- to 8-month primary angiographic end
oint. Data comparisons at 2 years may be regarded as post
oc and hypothesis generating. Regarding safety outcomes,
his study was not powered to detect a difference in relatively
arely occurring clinical events such as death, myocardial
nfarction, and stent thrombosis. In fact, to date, it has not
een possible for any study to show a significant difference
n rates of stent thrombosis between newer generation
olymer-free or biodegradable polymer DES as compared
ith established polymer-based DES. This is likely related
o the rarity of this complication. It is hoped that aggregate
ong-term data from recent large-scale studies will provide a
ramework for testing the hypothesized safety advantage of
hese platforms over the years to come (21,22).
1onclusions
he results of the ISAR-TEST-2 trial revealed no evidence
f a differential safety profile between the Cypher SES, a
ovel polymer-free sirolimus- and probucol-eluting Dual-
ES, and the Endeavor ZES out to 2 years. Furthermore,
he antirestenotic efficacy of both the Dual-DES and the
ES remained durable between 1 and 2 years, with Dual-
ES maintaining an advantage over the entire 2-year
eriod.
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